These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35610105)

  • 1. Risk-based cost-benefit analysis of alternative vaccines against COVID-19 in Brazil: Coronavac vs. Astrazeneca vs. Pfizer.
    Siqueira PG; Duarte HO; Moura MDC
    Vaccine; 2022 Jun; 40(28):3851-3860. PubMed ID: 35610105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs.
    Moreira RDS; Costa EG; Dos Santos LFR; Miranda LHL; de Oliveira RR; Romão RF; Cozer RF; Guedes SC
    BMC Infect Dis; 2022 May; 22(1):473. PubMed ID: 35581560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The hindrances to perform the COVID-19 vaccination in Brazil.
    Boschiero MN; Palamim CVC; Marson FAL
    Hum Vaccin Immunother; 2021 Nov; 17(11):3989-4004. PubMed ID: 34353218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation for mass vaccination against COVID-19.
    Wang WC; Fann JC; Chang RE; Jeng YC; Hsu CY; Chen HH; Liu JT; Yen AM
    J Formos Med Assoc; 2021 Jun; 120 Suppl 1():S95-S105. PubMed ID: 34108119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine.
    Farias JP; da Silva PS; Fogaça MMC; Santana IVR; Luiz WB; Birbrair A; Amorim JH
    J Virol; 2022 Apr; 96(8):e0017722. PubMed ID: 35389263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative Analyses of IgA Antibody Response of Non-COVID-19 Infected People Over 60 Years Old Following CoronaVac and Pfizer-BioNTech COVID-19 Vaccination].
    Yürüker Ö; Yetkin O; Güvenir M
    Mikrobiyol Bul; 2023 Apr; 57(2):330-333. PubMed ID: 37067217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) in the United States.
    Di Fusco M; Marczell K; Thoburn E; Wiemken TL; Yang J; Yarnoff B
    J Med Econ; 2023; 26(1):509-524. PubMed ID: 36942976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost Utility of Vaccination Against COVID-19 in Brazil.
    Fernandes RRA; Santos MDS; Magliano CADS; Tura BR; Macedo LSDN; Padila MP; França ACW; Braga AA
    Value Health Reg Issues; 2022 Sep; 31():18-24. PubMed ID: 35325693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation.
    Sandmann FG; Davies NG; Vassall A; Edmunds WJ; Jit M;
    Lancet Infect Dis; 2021 Jul; 21(7):962-974. PubMed ID: 33743846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the adverse events of Oxford-AstraZeneca, Pfizer-BioNTech, Moderna, and Johnson and Johnson COVID-19 vaccination on Guillain-Barré Syndrome.
    Meo SA; Shaikh N; Abukhalaf FA; Meo AS
    Sci Rep; 2024 Aug; 14(1):18767. PubMed ID: 39138276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 Vaccine Perception in South Korea: Web Crawling Approach.
    Lee H; Noh EB; Park SJ; Nam HK; Lee TH; Lee GR; Nam EW
    JMIR Public Health Surveill; 2021 Sep; 7(9):e31409. PubMed ID: 34348890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
    Cerqueira-Silva T; Andrews JR; Boaventura VS; Ranzani OT; de Araújo Oliveira V; Paixão ES; Júnior JB; Machado TM; Hitchings MDT; Dorion M; Lind ML; Penna GO; Cummings DAT; Dean NE; Werneck GL; Pearce N; Barreto ML; Ko AI; Croda J; Barral-Netto M
    Lancet Infect Dis; 2022 Jun; 22(6):791-801. PubMed ID: 35366959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies.
    Fu Y; Zhao J; Wei X; Han P; Yang L; Ren T; Zhan S; Li L
    Front Public Health; 2022; 10():917732. PubMed ID: 35928479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca Vaccines to Prevent Severe COVID-19 in Costa Rica: Nationwide, Ecological Study of Hospitalization Prevalence.
    Rosero-Bixby L
    JMIR Public Health Surveill; 2022 May; 8(5):e35054. PubMed ID: 35483079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
    Lopez Bernal J; Andrews N; Gower C; Robertson C; Stowe J; Tessier E; Simmons R; Cottrell S; Roberts R; O'Doherty M; Brown K; Cameron C; Stockton D; McMenamin J; Ramsay M
    BMJ; 2021 May; 373():n1088. PubMed ID: 33985964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.
    Pearson CAB; Bozzani F; Procter SR; Davies NG; Huda M; Jensen HT; Keogh-Brown M; Khalid M; Sweeney S; Torres-Rueda S; ; ; Eggo RM; Vassall A; Jit M
    PLoS Med; 2021 Oct; 18(10):e1003815. PubMed ID: 34606520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.